Xiaoyu Xie

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2).

Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2).

Journal: Med (New York, N.Y.)
Published: March 11, 2026

Broad-Spectrum Quorum Quenching and Biocontrol Potential of Pseudomonas procumbens sp. nov. and Pseudomonas polia sp. nov. via Degradation of Multiple Quorum Sensing Molecules.

Broad-Spectrum Quorum Quenching and Biocontrol Potential of Pseudomonas procumbens sp. nov. and Pseudomonas polia sp. nov. via Degradation of Multiple Quorum Sensing Molecules.

Journal: Journal of agricultural and food chemistry
Published: March 09, 2026

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: February 25, 2026

Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Journal: Nature communications
Published: October 21, 2025

Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial.

Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial.

Journal: EClinicalMedicine
Published: July 28, 2025

Unraveling the Complex Physiological, Biochemical, and Transcriptomic Responses of Pea Sprouts to Salinity Stress.

Unraveling the Complex Physiological, Biochemical, and Transcriptomic Responses of Pea Sprouts to Salinity Stress.

Journal: Genes
Published: June 16, 2025

TRIM29 promotes liver metastasis via enhancing hepatic colonization by stabilizing FAM83H to regulate keratin network in colorectal cancer.

TRIM29 promotes liver metastasis via enhancing hepatic colonization by stabilizing FAM83H to regulate keratin network in colorectal cancer.

Journal: Cellular signalling
Published: April 01, 2025

The value of pharmacist medication therapy management of capecitabine.

The value of pharmacist medication therapy management of capecitabine.

Journal: Frontiers in pharmacology
Published: March 27, 2025

Circulating Tumor DNA Predicts Conversion Therapy Response and Prognosis in Initially Unresectable Colorectal Liver-Limited Metastases: A Retrospective Study.

Circulating Tumor DNA Predicts Conversion Therapy Response and Prognosis in Initially Unresectable Colorectal Liver-Limited Metastases: A Retrospective Study.

Journal: British journal of hospital medicine (London, England : 2005)
Published: March 26, 2025

Combining Circulating Tumour DNA with Clinical Pathological Risk Factors for Developing Peritoneal Metastasis Prediction Model in Patients with Colorectal Cancer.

Combining Circulating Tumour DNA with Clinical Pathological Risk Factors for Developing Peritoneal Metastasis Prediction Model in Patients with Colorectal Cancer.

Journal: British journal of hospital medicine (London, England : 2005)
Published: February 25, 2025

Insights into immune-related adverse events in colorectal cancer patients receiving neoadjuvant immunotherapy: findings from a multicenter registry study.

Insights into immune-related adverse events in colorectal cancer patients receiving neoadjuvant immunotherapy: findings from a multicenter registry study.

Journal: Frontiers in immunology
Published: November 17, 2024

Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis.

Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis.

Journal: Cell death & disease
Published: August 21, 2024
Showing 1-12 of 26

Last Updated: 09/26/2026